Cambridge University spin-out Owlsense to form its own medtech startup.

Owlsense, a spin-out of Cambridge University, is to form a new company to commercialise research into a breathalyser that can identify diseases.

The medtech spin-out of Owlsense will be looking to raise somewhere between $3m-$5m to launch with, allowing Owlsense to continue its primary chemical detection nanochip business without being impeded by the breathalyser technology.

The device can detect cancer and other diseases such as diabetes and tuberculosis from a user’s breath, heightening the chances of early detection and thusly…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?